We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02529059
First Posted: August 19, 2015
Last Update Posted: September 18, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Gilead Sciences
Information provided by (Responsible Party):
St Stephens Aids Trust
  Purpose
This study aims to investigate whether substitution of Efavirenz (EFV) as the Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) fixed-dose combination (FDC) Atripla, with Rilpivirine as the tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) fixed-dose combination (FDC) Eviplera, leads to resolution of covert Central Nervous System (CNS) toxicity associated with EFV, continued virological suppression and immunological reconstitution and whether this is associated with an improvement in quality of life, sleep, anxiety/depression and neurocognitive function; the impact of switch on adherence will also be investigated.

Condition Intervention Phase
HIV Drug: Eviplera Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IV, Open-label, Multi Centre Pilot Study to Assess Changes in Cerebral Function Parameters in Patients Without Perceived Central Nervous System (CNS) Symptoms When Switched From a Fixed Dose Combination of Tenofovir/Emtricitabine/Efavirenz (Atripla®) to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine (Eviplera®)

Resource links provided by NLM:


Further study details as provided by St Stephens Aids Trust:

Primary Outcome Measures:
  • Change in neuropsychiatric and central nervous system (CNS) parameters after switching from Atripla to TDF/FTC/RPV at 4 weeks compared to baseline, as measured by the proportion of patients experiencing grade 2-4 neuropsychiatric and CNS toxicity [ Time Frame: 4 Weeks compared to baseline ]
    As defined by the ACTG Adverse event scale and collected by CNS questionnaire.

  • Change in neuropsychiatric and central nervous system (CNS) parameters after switching from Atripla to TDF/FTC/RPV at 4 weeks compared to baseline, as measured by the median number of grade 2-4 neuropsychiatric and CNS toxicity [ Time Frame: 4 Weeks compared to baseline ]
    As defined by the ACTG adverse event scale and collected by CNS questionnaire.

  • Change in neuropsychiatric and central nervous system (CNS) parameters after switching from Atripla to TDF/FTC/RPV at 4 weeks compared to baseline, as measured by the median CNS score. [ Time Frame: 4 Weeks compared to baseline ]
    Derived from the sum of toxicity of all grades collected in the CNS questionnaire.

  • Change in neuropsychiatric and central nervous system (CNS) parameters after switching from Atripla to TDF/FTC/RPV at 4 weeks compared to baseline, as measured by the change in sleep score using the Pittsburgh Sleep Questionnaire. [ Time Frame: 4 Weeks compared to baseline ]

Secondary Outcome Measures:
  • Change in neuropsychiatric and central nervous system (CNS) parameters after switching from Atripla to TDF/FTC/RPV at 12 & 24 weeks compared to baseline, as measured by proportion of patients experiencing grade 2-4 neuropsychiatric and CNS toxicity. [ Time Frame: 12 and 24 weeks compared to baseline ]
    As defined by the ACTG adverse event scale and collected by CNS questionnaire.

  • Change in neuropsychiatric and central nervous system (CNS) parameters after switching from Atripla to TDF/FTC/RPV at 12 and 24 weeks compared to baseline, as measured by the median number of grade 2-4 neuropsychiatric and CNS toxicity. [ Time Frame: 12 and 24 weeks compared to baseline ]
    As defined by the ACTG adverse event scale and collected by CNS questionnaire.

  • Change in neuropsychiatric and central nervous system (CNS) parameters after switching from Atripla to TDF/FTC/RPV at 12 and 24 weeks compared to baseline, as measured by the median CNS score [ Time Frame: 12 and 24 weeks compared to baseline ]
    Median CNS score is derived from the sum of toxicity of all grades collected in the CNS questionnaire.

  • Change in neuropsychiatric and central nervous system (CNS) parameters after switching from Atripla to TDF/FTC/RPV at 12 and 24 weeks compared to baseline, as measured by change in sleep score using the Pittsburgh Sleep Questionnaire. [ Time Frame: 12 and 24 weeks compared to baseline ]
  • Change in neuropsychiatric and CNS parameters as measured by the change in the Hospital Anxiety and Depression Scale (HADS) at 4, 12 and 24 weeks as compared with baseline. [ Time Frame: 4, 12 and 24 weeks compared to baseline ]
  • Proportion of patients with undetectable viral load (by local assay) at weeks 4, 12 and 24. [ Time Frame: 4, 12 and 24 weeks compared to baseline ]
  • Proportion of patients with viral load below 400 copies/mL at weeks 4, 12 and 24. [ Time Frame: 4, 12 and 24 weeks compared to baseline ]
  • Change in CD4+ count at week 12 and 24 compared to baseline. [ Time Frame: 12 and 24 weeks compared to baseline ]
  • Proportion of patients with grade 2-4 laboratory adverse events (excluding lipids) and proportion of patients with grade 2-4 non-CNS adverse events at 4, 12 and 24 weeks compared with baseline. [ Time Frame: 4, 12 and 24 weeks compared to baseline ]
  • Change in mean fasting cholesterol (total, HDL, LDL and total:HDL ratio) and triglycerides after 4, 12 and 24 weeks compared with baseline. [ Time Frame: 4, 12 and 24 weeks compared to baseline ]
  • Change in quality of life (as assessed by EQ-5D questionnaire) at 4, 12 and 24 weeks compared with baseline. [ Time Frame: 4, 12 and 24 weeks compared to baseline ]
  • Change in neurocognitive function as determined by computerised neurocognitive assessment (no computerised cognitive testing at week 12) [ Time Frame: 4, 12 and 24 weeks compared to baseline ]
  • Change in neurocognitive function as determined by Instrumental Activities of Daily Life (IADL) questionnaire [ Time Frame: 4, 12 and 24 weeks compared to baseline ]
  • Change in adherence as measured by the adherence questionnaire: Medication Adherence Self-Report Inventory (M-MASRI) at 12 and 24 weeks compared with baseline. [ Time Frame: 12 and 24 weeks compared to baseline ]
  • Change in cerebral MR-measurable imaging modalities at 24 weeks compared with baseline. [ Time Frame: 24 weeks compared to baseline ]

Estimated Enrollment: 40
Study Start Date: November 2015
Study Completion Date: May 2017
Primary Completion Date: May 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Switch from Atripla to Eviplera Drug: Eviplera
A single-pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily for 24 weeks.
Other Name: Rilpivirine, tenofovir, emtricitabine

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patient volunteers who meet all of the following criteria are eligible for this trial:

  1. Is male or female aged 18 years or above
  2. Has HIV-1 infection documented in their medical notes
  3. Has signed the Informed Consent Form voluntarily
  4. Is willing to comply with the protocol requirements
  5. Has been on Atripla for at least 12 weeks before enrolment
  6. Has an undetectable HIV-plasma viral load at screening by local assay (single re-test allowed)
  7. Has a CD4 cell count at screening >50 cells/mm3
  8. Has an estimated glomerular filtration rate (MDRD) >50 ml/min.
  9. Has no significant CNS symptoms which may be attributable to EFV.
  10. If female and of childbearing potential, is using effective birth control methods (for example, hormonal contraceptive, condom, abstinence, IUD, as agreed by the investigator) and is willing to continue practising these birth control methods during the trial and for at least 30 days after the end of the trial. Note: Women who are postmenopausal for least 2 years, women with total hysterectomy, and women who have a tubal ligation are considered of non-childbearing potential
  11. If a heterosexually active male, he is using effective birth control methods and is willing to continue practising these birth control methods during the trial and until follow-up visit

Exclusion Criteria:

Patients meeting 1 or more of the following criteria cannot be selected:

  1. Infected with HIV-2
  2. Using any concomitant therapy disallowed as per SPC for the study drugs (e.g proton pump inhibitors )
  3. Has acute viral hepatitis including, but not limited to, A, B, or C
  4. Has chronic hepatitis B and/or C with AST and/or ALT >5 x ULN Note: Patients can enter trial with chronic HBV if HBV-DNA undetectable at screen (and no detectable result in last 6 months) and with chronic HCV if not expected to require treatment during the trial period.
  5. Any investigational drug within 30 days prior to the trial drug administration
  6. Has ever received rilpivirine in the past
  7. Any clinical evidence of baseline resistance mutations, prior to commencing antiretroviral therapy.
  8. Known allergy to lactose monohydrate, sunset yellow aluminium lake (E110), and patients with galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption
  9. Severe hepatic impairment (defined as Child-Pugh-Turcotte (CPT) Score C).
  10. If female, she is pregnant or breastfeeding
  11. Screening blood result with any grade 3/4 toxicity according to Division of AIDS (DAIDS) grading scale, except: asymptomatic grade 3 glucose, amylase or lipid elevation or asymptomatic grade 4 triglyceride elevation (re-test allowed).
  12. Any condition (including drug/alcohol abuse) or laboratory results which, in the investigator's opinion, interfere with assessments or completion of the trial.
  13. If participating in the MR Imaging substudy, any contraindications to magnetic resonance scanning according to local radiology guidelines (to be assessed by MR Spectroscopy Imaging Department)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02529059


Locations
United Kingdom
Brighton & Sussex University Hospitals Nhs Trust
Brighton, United Kingdom
St. Mary's Hospital
London, United Kingdom
St. Stephen's Centre
London, United Kingdom
Sponsors and Collaborators
St Stephens Aids Trust
Gilead Sciences
Investigators
Principal Investigator: Mark Nelson St Stephen's AIDs Trust
  More Information

Responsible Party: St Stephens Aids Trust
ClinicalTrials.gov Identifier: NCT02529059     History of Changes
Other Study ID Numbers: SSAT058
First Submitted: May 27, 2015
First Posted: August 19, 2015
Last Update Posted: September 18, 2017
Last Verified: September 2017

Additional relevant MeSH terms:
Tenofovir
Emtricitabine
Rilpivirine
Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Anti-HIV Agents